| Schedule of net loss attributable to non-controlling interest |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net loss for the three months ended March 31, 2026 |
|
$ |
(269,652 |
) |
|
$ |
- |
|
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
|
(65,256 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
Net loss for the three months ended June 30, 2026 |
|
|
(287,410 |
) |
|
|
- |
|
Average Non-controlling interest percentage of profit/losses |
|
|
12.85 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
|
(36,932 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
Net loss for the three months ended September 30, 2026 |
|
|
(105,363 |
) |
|
|
- |
|
Average Non-controlling interest percentage of profit/losses |
|
|
12.85 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
|
(13,539 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
Total |
|
|
(115,727 |
) |
|
|
- |
|
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net loss for the three months ended March 31, 2025 |
|
$ |
(42,784 |
) |
|
$ |
(10 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
|
(10,354 |
) |
|
|
(3 |
) |
|
|
|
|
|
|
|
|
|
Net loss for the three months ended June 30, 2025 |
|
|
(594,446 |
) |
|
|
(5 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
|
(143,856 |
) |
|
|
(2 |
) |
|
|
|
|
|
|
|
|
|
Net loss for the three months ended September 30, 2025 |
|
|
147,763 |
|
|
|
- |
|
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
|
35,759 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Total |
|
|
(118,451 |
) |
|
|
(5 |
) |
|
| Schedule of changes in non-controlling interest |
Balance, December 31, 2025 |
|
$ |
(303,429 |
) |
Net loss attributable to the non-controlling interest |
|
|
(115,727 |
) |
Acquisition of non-controlling interest by the Company |
|
|
158,835 |
|
Balance, September 30, 2026 |
|
|
(260,321 |
) |
Balance, December 31, 2024 |
|
$ |
(234,812 |
) |
Net loss attributable to the non-controlling interest |
|
|
(118,456 |
) |
Balance, September 30, 2025 |
|
|
(353,268 |
) |
|